Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 6/20 | 0.67 |
| ▸ | F10 | P00742 | 5/20 | 0.67 |
| ▸ | PLAU | P00749 | 2/20 | 0.67 |
| ▸ | F2 | P00734 | 2/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.59 |
| ▸ | F12 | P00748 | 1/20 | 0.55 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.55 |
| ▸ | PROC | P04070 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29651383 | 1.00 | PLG (0.67) | PLGF10PLAUF2PRSS1 | |
| SCHEMBL8144360 | 1.00 | PLG (0.67) | PLGF10PLAUF2PRSS1 | |
| SCHEMBL29514928 | 1.00 | PLG (0.67) | PLGF10PLAUF2PRSS1 | |
| SCHEMBL9189122 | 1.00 | PLG (0.67) | PLGF10PLAUF2PRSS1 | |
| SCHEMBL7439785 | 0.89 | PLG (0.83) | PLGF10PLAUF12KLKB1 | |
| SCHEMBL3057528 | 0.86 | F2 (0.60) | PLGF10PLAUF2 | |
| SCHEMBL3419341 | 0.86 | F2 (0.60) | PLGF10PLAUF2 | |
| SCHEMBL4968238 | 0.85 | PLG (0.62) | PLGF10PLAUF2PRSS1 | |
| Piperidine SCHEMBL7370685 | 0.84 | F2 (0.53) | PLGF10PLAUF2PRSS1 | |
| SCHEMBL6787527 | 0.84 | PLG (0.54) | PLGF10PLAUF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376074-B1 | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2019-03-13 | — | — | EP | disclosed |
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
| US-4791102-A | ANTICOAGULANTS | SANOFI (FR) | 1988-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | CYP2B6, CYP1A2, CYP2D6 | PLG 369/4885F10 1069/4885PLAU 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.